ProQR Therapeutics (NASDAQ:PRQR) Releases Earnings Results, Beats Estimates By $0.04 EPS

ProQR Therapeutics (NASDAQ:PRQR) issued its earnings results on Thursday. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.04, reports. The company had revenue of $10.00 million during the quarter, compared to the consensus estimate of $4.56 million. ProQR Therapeutics had a negative net margin of 331.33% and a negative return on equity of 84.87%.

ProQR Therapeutics Price Performance

Shares of NASDAQ PRQR traded up $0.07 during mid-day trading on Friday, hitting $1.92. 487,193 shares of the company’s stock traded hands, compared to its average volume of 810,560. ProQR Therapeutics has a 1 year low of $1.33 and a 1 year high of $3.10. The company’s 50-day moving average is $1.74 and its two-hundred day moving average is $1.66. The company has a market capitalization of $202.29 million, a P/E ratio of -3.84 and a beta of 0.07.

Analyst Upgrades and Downgrades

PRQR has been the subject of several research analyst reports. Weiss Ratings cut ProQR Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, June 23rd. JonesTrading reduced their price objective on shares of ProQR Therapeutics from $11.00 to $10.00 and set a “buy” rating on the stock in a research report on Friday, June 26th. Wall Street Zen downgraded shares of ProQR Therapeutics from a “hold” rating to a “strong sell” rating in a report on Saturday, May 16th. Chardan Capital reduced their price target on shares of ProQR Therapeutics from $4.00 to $3.00 and set a “buy” rating on the stock in a report on Friday, June 26th. Finally, Citigroup reissued a “market outperform” rating on shares of ProQR Therapeutics in a report on Wednesday, May 27th. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $7.33.

Insider Activity at ProQR Therapeutics

In related news, Director Bart Filius bought 150,000 shares of the business’s stock in a transaction dated Friday, July 17th. The shares were purchased at an average price of $1.72 per share, with a total value of $258,000.00. Following the transaction, the director owned 300,000 shares in the company, valued at $516,000. This trade represents a 100.00% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Boer Daniel Anton De purchased 150,000 shares of the firm’s stock in a transaction that occurred on Thursday, July 9th. The shares were bought at an average price of $1.74 per share, for a total transaction of $261,000.00. Following the acquisition, the chief executive officer directly owned 300,000 shares in the company, valued at $522,000. This trade represents a 100.00% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired 600,000 shares of company stock worth $988,500 over the last three months. 8.40% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Invesco Ltd. purchased a new stake in shares of ProQR Therapeutics in the fourth quarter valued at $51,000. XTX Topco Ltd boosted its stake in shares of ProQR Therapeutics by 1,057.4% during the 4th quarter. XTX Topco Ltd now owns 117,900 shares of the biopharmaceutical company’s stock worth $238,000 after purchasing an additional 107,713 shares during the period. Ikarian Capital LLC grew its holdings in ProQR Therapeutics by 67.2% during the 4th quarter. Ikarian Capital LLC now owns 1,492,229 shares of the biopharmaceutical company’s stock valued at $3,014,000 after purchasing an additional 600,000 shares during the last quarter. Quadrature Capital Ltd raised its position in ProQR Therapeutics by 188.4% in the 4th quarter. Quadrature Capital Ltd now owns 104,231 shares of the biopharmaceutical company’s stock worth $211,000 after purchasing an additional 68,091 shares during the period. Finally, Millennium Management LLC lifted its stake in ProQR Therapeutics by 80.8% in the fourth quarter. Millennium Management LLC now owns 434,991 shares of the biopharmaceutical company’s stock worth $879,000 after purchasing an additional 194,369 shares during the last quarter. 32.65% of the stock is owned by hedge funds and other institutional investors.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.